Literature DB >> 11425374

Use of pentoxifylline in membranous nephropathy.

D Ducloux, C Bresson-Vautrin, J Chalopin.   

Abstract

Urinary TNF-alpha excretion correlates with proteinuria in patients with membranous nephropathy (MGN). Pentoxifylline suppresses or reduces the production of TNF-alpha. Between April, 1999 and August, 2000, we did a single-centre, prospective, pilot study to assess the effects of pentoxifylline (1200 mg/day) on proteinuria in patients with idiopathic MGN. Ten patients were included and treated for 6 months. Pentoxifylline significantly decreased proteinuria from 11 g/day [range 4.6-27] to 1.8 (0-10.9); p=0.001). Pentoxifylline may be a safe and effective adjunct to steroids and immunosuppressants in patients with MGN.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11425374     DOI： 10.1016/s0140-6736(00)04830-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  13 in total

1.  Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling.

Authors:  Yung-Ming Chen; Wen-Chih Chiang; Yalin Yang; Chun-Fu Lai; Kwan-Dun Wu; Shuei-Liong Lin
Journal:  Mol Med       Date:  2015-04-13       Impact factor: 6.354

Review 2.  Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis.

Authors:  Xiangpin Jiang; Shengguo Zhou; Jing Yao; Xianglei Kong; Meiyu Cui
Journal:  J Nephrol       Date:  2015-10-28       Impact factor: 3.902

3.  Protective effect of pentoxifylline on oxidative renal cell injury associated with renal crystal formation in a hyperoxaluric rat model.

Authors:  Hayrettin Ozturk; Ayhan Cetinkaya; Tulin Siviloglu Firat; Buket Kin Tekce; Selma Erdogan Duzcu; Hulya Ozturk
Journal:  Urolithiasis       Date:  2018-07-06       Impact factor: 3.436

Review 4.  Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.

Authors:  Judit Gordon; Jeffrey B Kopp
Journal:  Adv Chronic Kidney Dis       Date:  2011-07       Impact factor: 3.620

5.  Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome.

Authors:  David Raveh; Ovadia Shemesh; Yaakov Jack Ashkenazi; Robert Winkler; Vivian Barak
Journal:  Pediatr Nephrol       Date:  2004-08-25       Impact factor: 3.714

6.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

Review 7.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

8.  Effects of pentoxifylline in adriamycin-induced renal disease in rats.

Authors:  Yusuf Usta; Ugur Burcin Ismailoglu; Aysin Bakkaloglu; Dicle Orhan; Nesrin Besbas; Inci Sahin-Erdemli; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

9.  Nephropathy in type 1 diabetes is diminished in carriers of HLA-DRB1*04: the genetics of kidneys in diabetes (GoKinD) study.

Authors:  Suzanne K Cordovado; Yuan Zhao; James H Warram; Hongguang Gong; Karen L Anderson; Miyono M Hendrix; Laura N Hancock; Patricia A Cleary; Patricia W Mueller
Journal:  Diabetes       Date:  2007-11-26       Impact factor: 9.461

10.  Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial.

Authors:  Shirinsadat Badri; Simin Dashti-Khavidaki; Farrokhlegha Ahmadi; Mitra Mahdavi-Mazdeh; Mohammad-Reza Abbasi; Hossein Khalili
Journal:  Clin Drug Investig       Date:  2013-03       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.